Publications by authors named "I P Trias"
Prognostic Expression Signature of , , and Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Eur Urol Open Sci
December 2024
Unlabelled: Alterations in the tumor suppressor genes (TSGs) , , and are associated with treatment resistance, worse survival, and aggressive variants of prostate cancer (AVPC). We previously developed and validated a signature reflecting low TSG expression (TSG) that was associated with poor outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) ± docetaxel. The aim of this multicenter retrospective study was to validate the TSG signature in patients with mHSPC treated with ADT and an androgen receptor pathway inhibitor (ARPI) and to explore clinical characteristics at progression according to TSG status.
View Article and Find Full Text PDFArticle Synopsis
- Scientists don't know much about vulvar squamous cell carcinoma (VSCC), a cancer mostly found in older women, especially about its mutations and how different types affect survival.
- In a study of 60 patients, they found three main types of VSCC related to the human papillomavirus (HPV) and some common gene mutations, particularly in the TP53 gene.
- Patients with mutations in TP53 and CCND1 had a much higher chance of their cancer coming back, suggesting that these changes could help doctors find better treatments for VSCC.
Article Synopsis
- - Penile squamous cell carcinoma (PSCC) is divided into two main types: HPV-associated and HPV-independent, with the prognosis being influenced by the status of the p53 protein, which is somewhat debated.
- - A study involving 122 PSCC patients explored the correlation between HPV and p53 status, categorizing tumors into three subtypes based on immunohistochemistry and HPV tests.
- - Results showed that patients with HPV-independent tumors and abnormal p53 patterns had significantly worse outcomes, with a higher rate of disease-related deaths compared to those with HPV-associated or HPV-independent/p53-normal tumors.
Background: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC).
Objective: To study the clinical implications of TSG mRNA expression in mHSPC patients.